Top 3 Stelara Manufacturers (2026 Audit Report)

H2: Market Trends for Stelara in 2026

In 2026, the market landscape for Stelara (ustekinumab), a biologic therapy developed by Johnson & Johnson for autoimmune diseases such as plaque psoriasis, psoriatic arthritis, Crohn’s disease, and ulcerative colitis, is shaped by several critical factors. Despite its longstanding success, Stelara faces increasing pressure from biosimilars, evolving treatment paradigms, and shifting payer dynamics.

1. Biosimilar Competition Intensifies
The most significant trend affecting Stelara in 2026 is the launch and growing penetration of biosimilars. In the United States, the first wave of ustekinumab biosimilars entered the market in January 2024 following the expiration of key patents. By 2026, multiple biosimilars from companies such as Amgen, Sandoz, and Samsung Bioepis are commercially available, driving substantial price competition. This has led to double-digit percentage declines in Stelara’s revenue year-over-year, with biosimilars capturing over 30% of the U.S. market share by mid-2026.

2. Market Share Erosion in Key Indications
Stelara continues to face competition not only from biosimilars but also from newer biologics and small molecules. In psoriasis and psoriatic arthritis, IL-23 inhibitors (e.g., Eli Lilly’s mirikizumab, Janssen’s guselkumab) offer improved efficacy and dosing convenience, capturing market share. In inflammatory bowel disease (IBD), therapies like risankizumab (AbbVie) and oral JAK inhibitors (e.g., upadacitinib) provide effective alternatives with more flexible administration routes, further challenging Stelara’s dominance.

3. Pricing and Reimbursement Pressures
Payers in both the U.S. and Europe are increasingly mandating biosimilar substitution and implementing step therapy protocols, requiring patients to fail on lower-cost agents before accessing originator biologics. This has reduced Stelara’s utilization in public and private insurance plans, particularly in the U.S. Medicaid programs and EU national health systems. J&J has responded with rebates and value-based contracting, but these measures have compressed margins.

4. Geographic Divergence in Market Performance
While Stelara is declining in mature markets like the U.S. and Western Europe, it maintains stronger performance in emerging markets such as parts of Latin America, the Middle East, and Asia-Pacific, where biosimilar adoption is slower and brand recognition remains high. J&J is focusing commercial efforts in these regions, leveraging Stelara’s established safety profile and physician familiarity.

5. Lifecycle Management and Pipeline Strategy
J&J is extending Stelara’s relevance through real-world evidence generation and label expansions. In 2026, post-marketing studies are underway to explore ustekinumab in new indications and pediatric populations. However, no major new formulations or delivery innovations are expected, limiting its ability to differentiate from competitors.

Conclusion
By 2026, Stelara remains a clinically important therapy but is in clear commercial decline due to biosimilar erosion and competitive innovation. Its future market position will depend on J&J’s ability to defend share in IBD and niche indications, support biosimilar transition strategies, and leverage global access programs. While Stelara will remain a key player in the autoimmune space, its peak revenue years are behind it, marking a transition from market leader to legacy biologic.

Common Pitfalls Sourcing Stelara (Quality, IP)

Sourcing Stelara (ustekinumab), a biologic medication used to treat autoimmune conditions like psoriasis, psoriatic arthritis, and Crohn’s disease, presents significant challenges related to both product quality and intellectual property (IP) rights. Falling into these pitfalls can lead to regulatory, legal, and patient safety issues.

Quality Risks and Counterfeit Products

One of the most critical pitfalls in sourcing Stelara is the risk of poor-quality or counterfeit products. Biologics like Stelara are highly complex and sensitive to manufacturing and storage conditions. Unauthorized suppliers may offer:

• Substandard formulations: Products that do not meet pharmaceutical purity, potency, or sterility standards, potentially endangering patient health.
• Counterfeit drugs: Fake versions that may contain incorrect active ingredients, wrong dosages, or harmful contaminants.
• Improper storage and handling: Stelara requires strict cold chain management. Sourcing through unregulated channels increases the risk of temperature excursions, leading to drug degradation and loss of efficacy.
• Lack of regulatory oversight: Non-authorized distributors may not comply with Good Distribution Practices (GDP) or be subject to regulatory inspections, increasing the risk of compromised product integrity.

Intellectual Property (IP) Infringement

Stelara is protected by robust intellectual property rights, including patents and data exclusivity, which vary by jurisdiction. Sourcing outside authorized channels can lead to IP violations, such as:

• Patent infringement: Importing or distributing Stelara without the patent holder’s (Johnson & Johnson/Janssen) authorization in countries where patents are still in force can result in legal action, product seizure, and financial penalties.
• Circumvention of regulatory pathways: Attempting to source biosimilars or unapproved versions before patent expiry may violate regulatory frameworks designed to protect innovation.
• Gray market risks: Parallel imports from lower-priced markets may infringe on the manufacturer’s market segmentation strategies and contractual agreements, leading to legal disputes and supply chain disruptions.

Ensuring compliance with both quality standards and IP laws is essential when sourcing Stelara. Engaging only with authorized distributors, verifying supply chain traceability, and staying informed about patent status in target markets are critical steps to avoid these common pitfalls.

Logistics & Compliance Guide for Stelara (ustekinumab)

This guide outlines essential logistics and compliance considerations for handling, distributing, and administering Stelara (ustekinumab), a biologic medication used to treat various autoimmune conditions. Adherence to these guidelines ensures patient safety, drug efficacy, and regulatory compliance.

Storage and Handling

Stelara must be stored under strict temperature control to maintain its stability and potency. Follow manufacturer and regulatory guidelines precisely:

• Refrigeration: Store Stelara at 2°C to 8°C (36°F to 46°F) in the original carton to protect from light.
• Do Not Freeze: Freezing can damage the protein structure. Discard any product that has been frozen.
• Avoid Shaking: Minimize agitation to prevent foaming or denaturation.
• In-Transit Requirements: Use validated cold chain packaging with temperature monitoring (e.g., data loggers) during shipping. Ensure delivery complies with GDP (Good Distribution Practice) standards.

Transportation and Distribution

Secure and temperature-controlled logistics are critical throughout the supply chain:

• Cold Chain Integrity: Maintain continuous temperature monitoring from manufacturer to pharmacy or healthcare provider.
• Authorized Distributors: Use only authorized and qualified distributors compliant with local and international regulations (e.g., FDA, EMA).
• Documentation: Retain shipping records, temperature logs, and chain of custody documentation for audit purposes.
• Expedited Shipping: Use time- and temperature-sensitive shipping methods, especially for patient-specific deliveries.

Regulatory and Compliance Requirements

Ensure all activities align with national and international regulatory standards:

• Licensing: Confirm that all storage and distribution facilities possess appropriate licenses (e.g., wholesale distribution authorization).
• GxP Compliance: Adhere to Good Manufacturing Practice (GMP), Good Distribution Practice (GDP), and Good Documentation Practice.
• Track and Trace: Implement systems to track Stelara batches for recalls and counterfeit detection (e.g., FDA DSCSA requirements in the U.S.).
• Import/Export Permits: For cross-border shipments, ensure compliance with customs and health authority regulations.

Dispensing and Administration

Healthcare providers must follow strict protocols when dispensing and administering Stelara:

• Prescription Verification: Confirm valid prescription and patient eligibility.
• Patient Counseling: Provide information on storage (if self-administered), injection technique, and adverse event reporting.
• Vaccination Screening: Assess patient’s vaccination status, especially for live vaccines, prior to initiating therapy.
• Controlled Substance Handling: While not a controlled substance, Stelara is a high-cost biologic requiring accountability and secure storage.

Adverse Event Reporting and Pharmacovigilance

Compliance with pharmacovigilance requirements is mandatory:

• Reporting Obligations: Healthcare providers and distributors must report adverse events and product quality complaints to relevant authorities (e.g., FDA MedWatch, EudraVigilance).
• Record Retention: Maintain records of adverse events, complaints, and investigations for a minimum of 10 years (or as per local regulation).

Product Recall and Returns

Establish procedures for managing product recalls or expired/compromised products:

• Recall Plan: Have a qualified recall procedure in place, including notification timelines and product retrieval.
• Quarantine: Immediately isolate any suspect or recalled product.
• Return Authorization: Only accept returns under authorized programs; do not re-dispatch returned products.

Training and Documentation

Ensure all personnel involved are properly trained and records are maintained:

• Staff Training: Train logistics, pharmacy, and clinical staff on handling, storage, and compliance protocols.
• Audit Readiness: Maintain accurate, legible, and contemporaneous records for regulatory inspections.
• Standard Operating Procedures (SOPs): Develop and regularly update SOPs for all aspects of Stelara management.

Adherence to this logistics and compliance guide helps ensure the safe and effective use of Stelara while meeting global regulatory expectations. Always consult the latest product labeling and local regulations for updates.

Declaration: Companies listed are verified based on web presence, factory images, and manufacturing DNA matching. Scores are algorithmically calculated.